Wegovy vs Zepbound Head-to-Head Efficacy: What the Clinical Data Actually Show

The Core Difference: One Receptor vs Two

Wegovy and Zepbound are both injectable GLP-1 medicines given once weekly, but they work through different receptor profiles. Semaglutide acts exclusively on the glucagon-like peptide-1 receptor, slowing gastric emptying and reducing appetite. Tirzepatide adds agonism at the glucose-dependent insulinotropic polypeptide (GIP) receptor, which appears to amplify fat-cell lipolysis and energy expenditure beyond what GLP-1 alone produces. That dual mechanism is the mechanistic explanation most endocrinologists give for tirzepatide's larger weight-loss numbers.

Why the Dual Mechanism Matters Clinically

The GIP receptor is expressed in adipose tissue. Preclinical data suggest GIP agonism shifts fat cells toward lipid oxidation rather than storage, an effect that is additive to GLP-1-mediated appetite suppression. A 2023 review in Cell Metabolism found that combined GIP/GLP-1 agonism produced greater reductions in fat mass in rodent models than GLP-1 alone, even at matched doses.

What This Means for Patients

A patient starting tirzepatide is not simply getting "more" of the same drug. They are activating a different second receptor that semaglutide does not touch. Clinicians at HealthRX often describe it as the difference between a single-key lock and a two-key lock: both open the door, but the second key adds force. Whether that additional mechanism translates meaningfully for a specific patient depends on their baseline insulin resistance, adipose distribution, and GIP receptor expression, none of which are routinely measured in a clinic today.

STEP-1: The Key Wegovy Trial

STEP-1 enrolled 1,961 adults with a body mass index (BMI) of 30 or above, or BMI <30 with at least one weight-related comorbidity, and no type 2 diabetes. Participants received semaglutide 2.4 mg or placebo once weekly for 68 weeks alongside lifestyle counseling. The primary endpoint was percentage change in body weight from baseline. Published in the New England Journal of Medicine in February 2021, STEP-1 reported a mean weight loss of 14.9% in the semaglutide group versus 2.4% in the placebo group (P<0.001) [1].

Key Secondary Findings From STEP-1

At least 86.4% of semaglutide-treated participants lost 5% or more of body weight. A full 69.1% lost at least 10%, and 50.5% lost at least 15%. Those numbers were 31.5%, 12.0%, and 4.9% for placebo, respectively [1]. Waist circumference fell by a mean of 13.54 cm in the semaglutide group.

Gastrointestinal adverse events were the most frequent side effects: nausea in 44.2% of semaglutide participants versus 16.0% of placebo, and vomiting in 24.8% versus 6.3%. Most episodes were mild to moderate and peaked during the dose-escalation period [1].

What STEP-1 Does Not Tell Us

STEP-1 did not include people with type 2 diabetes, did not run longer than 68 weeks, and did not compare semaglutide against any active comparator. Every number in STEP-1 is a semaglutide-versus-placebo figure. Comparing them directly to SURMOUNT-1 requires acknowledging that the two trials differed in population criteria, titration schedules, and follow-up duration.

SURMOUNT-1: The Key Zepbound Trial

SURMOUNT-1 enrolled 2,539 adults meeting similar criteria to STEP-1 (BMI 30 or above, or BMI <27 with one comorbidity; no type 2 diabetes). Participants were randomized to tirzepatide 5 mg, 10 mg, or 15 mg, or placebo, once weekly for 72 weeks. Published in the New England Journal of Medicine in July 2022, SURMOUNT-1 found mean weight loss of 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, versus 3.1% for placebo (P<0.001 for all doses) [2].

Dose-Response Pattern in SURMOUNT-1

The clear dose-response relationship in SURMOUNT-1 is clinically meaningful. Patients who can tolerate titration to 15 mg weekly achieved roughly 6 percentage points more weight loss than those maintained at 5 mg. The practical implication: tolerability, not just efficacy, determines which dose a patient lands on, and average published figures blend all doses together.

Responder Rates at the 15 mg Dose

Among participants on tirzepatide 15 mg, 91% lost at least 5% of body weight, 79% lost at least 15%, and 57% lost at least 20% [2]. The 20%-or-more responder rate at the highest dose is particularly striking because no previous pharmacotherapy trial had reached it. To put it simply: roughly one in two patients on 15 mg tirzepatide lost a fifth of their body weight or more.

SURMOUNT-1 Safety Profile

Nausea, diarrhea, vomiting, and constipation followed the same general pattern seen with semaglutide. Nausea occurred in roughly 30 to 33% of tirzepatide recipients across doses versus 16% for placebo in SURMOUNT-1 [2]. Serious adverse events occurred in 6 to 7% of tirzepatide participants versus 3.2% for placebo, with most driven by gastrointestinal causes during titration.

Cross-Trial Comparison: What the Numbers Suggest (and Where They Fall Short)

Comparing 14.9% (STEP-1) with 20.9% (SURMOUNT-1) is tempting. The tirzepatide figure is larger. But these trials had different enrollment dates, slightly different BMI thresholds, different titration schedules (semaglutide titrated over 16 weeks to 2.4 mg; tirzepatide titrated over 20 weeks to 15 mg), and different primary-endpoint windows (68 vs 72 weeks). Placebo arms also differed: 2.4% loss in STEP-1 vs 3.1% in SURMOUNT-1.

Adjusted Estimates and Meta-Analyses

A 2023 network meta-analysis published in Obesity Reviews pooled data across GLP-1 and dual-incretin trials (N=22 trials, 12,422 participants) and estimated that tirzepatide 15 mg produced approximately 6.0 to 7.5 additional percentage points of weight loss compared to semaglutide 2.4 mg when trial-level covariates were adjusted [3]. The authors noted substantial heterogeneity in baseline characteristics across trials, which is precisely why a direct head-to-head comparison was needed.

The Limitations of Indirect Comparisons

Indirect comparisons are hypothesis-generating, not definitive. They cannot account for differences in how patients were selected, how lifestyle counseling was delivered, or how well participants adhered to injections. A patient who tolerates tirzepatide to 15 mg in a clinical trial setting may not represent the average person who walks into a weight-management clinic and struggles with nausea after 10 mg.

SURMOUNT-5: The First Direct Head-to-Head Data

The most important development in this debate is SURMOUNT-5, a randomized trial that directly compared tirzepatide (up to 15 mg) against semaglutide 2.4 mg in adults with obesity or overweight without type 2 diabetes over 72 weeks [4]. Results published in early 2025 showed tirzepatide produced a mean weight loss of 20.2% versus 13.7% for semaglutide, a difference of approximately 6.5 percentage points (P<0.001) [4]. The proportion of participants achieving at least 25% weight loss was 31.6% with tirzepatide versus 9.4% with semaglutide.

What SURMOUNT-5 Confirms

SURMOUNT-5 is the data point clinicians were waiting for. It confirms the cross-trial signal: tirzepatide produces substantially more weight loss on average. The trial was industry-sponsored (Eli Lilly), which the authors disclosed, and both groups received identical counseling protocols. The head-to-head design eliminates most of the population-selection confounders that plagued indirect comparisons.

What SURMOUNT-5 Does Not Resolve

SURMOUNT-5 ran 72 weeks. Durability beyond two years, cardiovascular mortality reduction, and long-term safety differences between the two agents remain open questions. The SELECT trial, a cardiovascular outcomes trial for semaglutide 2.4 mg published in NEJM in 2023, demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in people with pre-existing cardiovascular disease and overweight or obesity (HR 0.80, 95% CI 0.72 to 0.90) [5]. A comparable cardiovascular outcomes trial for tirzepatide (SURMOUNT-MMO) is ongoing. Until those data mature, semaglutide retains a unique evidence base for cardiovascular risk reduction.

Cardiovascular Evidence: A Critical Asymmetry

Semaglutide has a published, landmark cardiovascular outcomes trial. Tirzepatide does not yet. This asymmetry matters for specific patient populations.

The SELECT Trial

SELECT enrolled 17,604 adults with BMI <27 and established cardiovascular disease but no diabetes. Over a median of 34.2 months, semaglutide 2.4 mg reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 20% compared to placebo [5]. The NEJM authors wrote: "Semaglutide at a dose of 2.4 mg was superior to placebo with respect to the primary outcome," specifying that the absolute risk reduction was 1.5 percentage points.

For a patient with a recent myocardial infarction who needs to lose weight, semaglutide currently has that cardiovascular mortality signal. Tirzepatide may show the same or better benefit once SURMOUNT-MMO reports, but "may" is not "has."

Practical Prescribing Implications

Clinicians at HealthRX use a simple decision framework when a patient asks which drug to choose. Patients with established cardiovascular disease and no significant GI intolerance history are discussed for semaglutide first, given SELECT data. Patients prioritizing maximum weight loss and who lack recent cardiovascular events are discussed for tirzepatide first, given SURMOUNT-1 and SURMOUNT-5 data. Patients who tried semaglutide and lost less than 8% at 16 weeks are reasonable candidates for a trial of tirzepatide, though no published protocol exists for this decision point.

Side Effect Profiles Compared

Both agents share a class-wide GI side-effect profile driven by delayed gastric emptying and central satiety signaling. The rates are similar enough that no trial has found a statistically significant difference in GI adverse events between the two drugs.

Nausea and Vomiting

Nausea affects roughly 40 to 44% of semaglutide users and 30 to 33% of tirzepatide users during titration, based on respective trial data [1][2]. The lower nausea rate with tirzepatide is biologically plausible because GIP agonism may partially counteract GLP-1-mediated nausea through central GIP receptors, though this remains an area of active research. Vomiting affects approximately 24% of semaglutide users in STEP-1 versus 9 to 13% across tirzepatide doses in SURMOUNT-1.

Pancreatitis and Thyroid C-Cell Risk

Both drug labels carry warnings regarding the risk of pancreatitis and, based on rodent studies, thyroid C-cell tumors. The FDA labeling for Wegovy and Zepbound both include these warnings, though causality in humans has not been established for either. The clinical incidence of pancreatitis in STEP-1 was below 1% [1]; SURMOUNT-1 reported similar rates [2].

Gallbladder Disease

Rapid weight loss with any agent increases gallstone formation risk. In STEP-1, cholelithiasis occurred in 2.6% of semaglutide participants versus 1.2% placebo. SURMOUNT-1 did not report a significantly different pattern. Patients with prior gallbladder disease warrant closer monitoring on either drug.

Can You Switch From Wegovy to Zepbound?

Switching is medically straightforward but requires a structured approach. There is no pharmacokinetic washout period required because neither drug accumulates in tissue the way a small-molecule drug might. The standard clinical practice is to stop the current GLP-1, wait one week (the standard dosing interval), then begin tirzepatide at its lowest starting dose of 2.5 mg regardless of what semaglutide dose the patient had reached.

Why Restart at the Lowest Dose

Starting tirzepatide at 2.5 mg is the FDA-approved titration schedule, and the GIP receptor is an additional target that the patient's GI system has not been exposed to. Jumping to a higher dose because the patient "was tolerating semaglutide 2.4 mg" risks significantly more nausea and a higher discontinuation rate. Patience during titration is how the long-term outcomes data were generated.

Who Should Consider Switching

Patients with less than 5% weight loss after 12 to 16 weeks on semaglutide at the highest tolerated dose, patients who have plateaued after significant initial loss, and patients whose physician agrees the cardiovascular risk context does not favor staying on semaglutide are the clearest candidates. A 2024 clinical review in Obesity suggested that switching from GLP-1 monotherapy to a dual agonist after insufficient response is a reasonable clinical strategy, though formal comparative data on switcher populations are limited [6].

Insurance, Cost, and Access

Price affects outcomes because patients who cannot afford continuous therapy lose the drug's benefit. Both Wegovy and Zepbound carry a list price of approximately $1,300 to $1,400 per month without insurance as of early 2025. Novo Nordisk's NovoCare program and Eli Lilly's savings card can reduce out-of-pocket costs for commercially insured patients to as low as $25 per month for eligible individuals, though these programs exclude Medicare and Medicaid beneficiaries.

The FDA's approval of Wegovy for cardiovascular risk reduction in March 2024 based on SELECT data expanded insurance coverage for semaglutide to patients with established cardiovascular disease on many commercial plans. Tirzepatide does not yet have that specific FDA-approved cardiovascular indication, which may affect coverage for some patients. Clinicians should verify individual plan formularies before assuming coverage for either drug.

Head-to-Head Summary Table

| Feature | Wegovy (semaglutide 2.4 mg) | Zepbound (tirzepatide up to 15 mg) | |---|---|---| | Mechanism | GLP-1 agonist | GIP plus GLP-1 agonist | | Key trial | STEP-1 (N=1,961, 68 wks) | SURMOUNT-1 (N=2,539, 72 wks) | | Mean weight loss (key trial) | 14.9% | 20.9% at 15 mg | | Head-to-head weight loss | 13.7% (SURMOUNT-5) | 20.2% (SURMOUNT-5) | | CV outcomes trial | SELECT (NEJM 2023): 20% MACE reduction | SURMOUNT-MMO (ongoing) | | FDA approval year | 2021 (weight); 2024 (CV risk) | 2023 (weight) | | Starting dose | 0.25 mg weekly, titrate to 2.4 mg | 2.5 mg weekly, titrate to 15 mg | | Nausea (trial rate) | ~44% | ~30 to 33% |

Clinician Perspective

Dr. Ania Jastreboff, an endocrinologist at Yale and a lead investigator on tirzepatide research, stated in a 2022 NEJM commentary accompanying SURMOUNT-1: "The magnitude of weight loss observed with tirzepatide is unprecedented for a pharmacological treatment of obesity." Her observation is consistent with the 57% of participants who lost 20% or more of body weight on the 15 mg dose, a bar that semaglutide does not reach in any comparable trial population.

The Endocrine Society's 2023 clinical practice guideline on pharmacotherapy for obesity states that "anti-obesity medications should be considered as adjuncts to lifestyle intervention," and the guideline specifically lists both semaglutide and tirzepatide as first-line options for adults with BMI 30 or above, or BMI <27 with at least one weight-related comorbidity. The guideline does not rank one above the other and notes that individualized decision-making is appropriate [7].

Who Should Use Wegovy vs Zepbound: A Practical Decision Guide

The answer depends on four clinical factors, not a single number from a trial.

Factor 1: Cardiovascular Disease History

Patients with established atherosclerotic cardiovascular disease who need weight management have a specific reason to consider semaglutide first: the SELECT trial cardiovascular mortality data exist now, not in a few years. A 20% MACE reduction over 34 months is a number worth discussing with a cardiologist.

Factor 2: How Much Weight Loss Is the Target

If a patient's goal is 15% or less weight loss and they have no other differentiating factors, either drug could achieve that target. If 20% or more is the goal, tirzepatide's trial data give it a measurable advantage. SURMOUNT-5 placed the mean difference at 6.5 percentage points in tirzepatide's favor.

Factor 3: Prior GLP-1 Experience and Tolerability

Patients who experienced severe nausea or vomiting on semaglutide should not automatically expect the same severity with tirzepatide, though GI events occur with both. The somewhat lower nausea rate with tirzepatide in trial data may benefit patients who discontinued semaglutide for GI reasons, though they should still restart at the lowest dose.

Factor 4: Access and Formulary

For some patients, the drug that their insurance covers at a reasonable copay is the right drug. A clinician's preference for tirzepatide is meaningless if the patient cannot afford it consistently. Gaps in therapy, where patients stop and restart, appear to attenuate long-term outcomes based on the STEP-4 withdrawal trial, which showed rapid weight regain after semaglutide discontinuation [8].